Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced that the National Medical Products Administration (NMPA) has accepted its clinical trial filing for the small molecule SAL0120, which is indicated for the treatment of IgA nephropathy.
SAL0120: An Endothelin Receptor Antagonist for Chronic Kidney Disease and Hypertension
SAL0120, an in-house developed endothelin (ET) receptor antagonist, is designed to address IgA nephropathy and mild to moderate primary hypertension. The company has initiated a Phase I clinical study for this molecule, focusing on its potential in managing primary hypertension.
Understanding the Role of Endothelin in Kidney Disease and Cardiovascular Health
Endothelin (ET), an endogenous vasoconstriction factor, is closely linked to the development and progression of chronic kidney disease and various cardiovascular diseases. ETA receptors, primarily found in smooth muscle cells, are known to mediate vascular smooth muscle cell proliferation, fibrosis, inflammatory responses, and vasoconstriction. SAL0120 selectively blocks ETA receptors, which can lead to blood vessel relaxation, thereby lowering blood pressure and providing cardiorenal protection. In the context of IgA nephropathy, SAL0120 is expected to mitigate ETA-mediated vasoconstriction, mesangial cell proliferation, extracellular matrix synthesis, podocyte dysfunction, and inflammatory reactions.-Fineline Info & Tech
